Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.

R B Jones1, E J Shpall, J Shogan

  • 1Duke University Bone Marrow Transplantation Program, Department of Medicine, Durham, North Carolina.

Cancer
|August 1, 1990
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.

Transplantation and cellular therapy·2021
Same author

The occurrence of inositolphosphoceramides in spirulina microalgae.

Electrophoresis·2020
Same author

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

Blood·2020
Same author

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Leukemia·2017
Same author

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Science (New York, N.Y.)·2017

The intensive induction chemotherapy regimen AFM, including Adriamycin, 5-fluorouracil, and methotrexate, showed a 91% overall response rate in metastatic breast cancer. While potent, its significant toxicity warrants cautious use in routine treatment.

Area of Science:

  • Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • Metastatic breast cancer presents a significant treatment challenge.
  • Effective induction chemotherapy is crucial for achieving tumor shrinkage before further treatment.
  • The AFM regimen was developed for intensive initial therapy.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of the AFM chemotherapy regimen in patients with metastatic breast cancer.
  • To assess the response rates and clinical outcomes associated with AFM induction therapy.

Main Methods:

  • A cohort of forty-five patients with metastatic breast cancer received the AFM regimen.
  • AFM consists of Adriamycin (doxorubicin), 5-fluorouracil, and methotrexate with folinic acid rescue.
  • Treatment was designed for rapid tumor debulking prior to high-dose chemotherapy with autologous marrow support.

Related Experiment Videos

Main Results:

  • An overall response rate of 91% was observed.
  • Complete clinical responses were achieved in 38% of patients.
  • Extensive hematologic and mucosal toxicity were noted, but no treatment-related deaths occurred.

Conclusions:

  • The AFM regimen is a potent option for inducing remission in metastatic breast cancer.
  • Considerable toxicity associated with AFM suggests careful consideration for its application in standard breast cancer treatment protocols.